瑞通立与尿激酶对急性心肌梗死患者疗效研究

Effect of Ruitongli and urokinase on acute myocardial infarction

目的观察研究重组人组织型纤溶酶原激酶衍生物(瑞通立)与尿激酶对基层医院急性ST段抬高型心肌梗死患者的疗效及安全性。方法收治入院的急性ST段抬高型心肌梗死患者中抽取90例,随机分为观察组与对照组,观察组患者使用瑞通立进行治疗,对照组患者使用尿激酶进行治疗,对比观察两组患者的治疗情况。结果观察组患者临床再通率明显高于对照组,严重心律失常发生率和出血并发症发生率明显低于对照组,差异有统计学意义(P﹤0.05);而35d死亡率、左室射血分数及住院时间数据相近,差异不具有统计学意义(P﹥0.05)。结论在基层医院使用瑞通立对急性ST段抬高型心肌梗死患者进行治疗,相比尿激酶具有更好的临床疗效,能有效增强临床再通率,降低严重心律失常发生及出血并发症,同时减少死亡率,加快患者康复速度,可以在临床上进一步推广应用。

Objective To observe the effect of recombinant human tissue type plasminogen kinase derivatives （ Ruitong Li ） and the safety and efficacy of urokinase in patients with acute ST segment elevation myocardial infarction in primary hospital. Methods From hospitalized patients with acute ST segment elevation myocardial infarction in the selected 90 cases,were randomly divided into observation group and control group, patients in the observation group use Ruitongli treatment, patients in the control group were treated with urokinase, comparative observation of treatment of two groups of patients. Results The patients in the observation group clinical recanalization rate was significantly higher than that of, the control group, severe arrhythmia incidence rate and complication rate was significantly lower than that of the control group, the difference was statistically significant （ P 〈 0. 05 ） ; and the 35 day mortality, left ventricular ejection fraction and time of hospitalization data are similar, the difference was not statistically significant （ P 〉 0. 05 ）. Conclusion The use of primary hospital in Ruitongli treatment for patients with acute ST segment elevation myocardial infarction, com- pared the clinical effects of urokinase has better, can effectively enhance the clinical recanalization rate, reduce complica- tions and bleeding serious arrhythmias, and reduce mortality, accelerate rehabilitation speed, can be further applied in clinic.